GEN Exclusives

More »

GEN News Highlights

More »
Jan 26, 2009

ThromboGenics and BioInvent Receive $6.5M Fee from Roche under Deal Covering Anticancer mAb

  • ThromboGenics and BioInvent received a technology transfer success fee of €5 million, or $6.5 million, from Roche. Payment is as per an alliance between the firms covering anticancer antibody, TB-403.

    The TB-403 strategic alliance with Roche was signed in June 2008. ThromboGenics and BioInvent received E50 million at the time and could earn up to E450 million following completion of a series of development and commercial milestones.

    Additionally Roche will pay double-digit royalties on future sales. ThromboGenics, which discovered TB-403, receives 60% and BioInvent 40% of the revenue from the deal.

    TB-403 is an anti-PIGF humanized mAb that blocks the formation of the new blood vessels required by solid tumors to support growth. PlGF is a homologue of VEGF, and clinical evidence suggests that it plays a role in the angiogenesis of malignant tissue and does not affect normal tissue angiogenesis.

    ---

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?